Clinical Safety of a Novel Milk Protein Peptide

Status Completed

Clinical Trial Summary

Background: A novel milk peptide has been shown in laboratory setting to have natural anti-cancer properties and extend lifespan and improve metabolism in animal models. The purpose of this study was 1.) to determine the safety dosage range and, 2.) to determine whether this novel milk peptide positively influence blood markers, metabolism and improve quality of life.

Clinical Trial Description

The study was conducted as a randomized, double-blind, placebo-controlled clinical trial in a university research setting. Healthy volunteers were randomly assigned to ingest in a double-blind and randomized manner either a placebo or milk peptides. Outcome measures were assessed at 0, 3, and 6 weeks of supplementation. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care

Related Conditions & MeSH terms

Drug Safety

Clinical Trial Details

NCT number	NCT01412658
Study type	Interventional
Source	Ambryx Biotechnology
Contact
Status	Completed
Phase	Phase 1
Start date	November 2006
Completion date	February 2007

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01425502` - Data-driven Quality Improvement in Primary Care - Trial	N/A
Recruiting	`NCT01756183` - Exploratory Study on the S-1 + Paclitaxel Chemotherapy for Unresectable Gastric Cancer	Phase 2
Completed	`NCT01757860` - Safety and Pharmacokinetics Study of CARD-024 in Healthy Subjects	Phase 1
Completed	`NCT01355016` - A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers	Phase 1
Completed	`NCT01179854` - Remegal Different Doses in Patients With Refractory Partial Seizures	Phase 2
Completed	`NCT00376415` - A Safety Study of Lessertia Frutescens in Adults.	Phase 1
Active, not recruiting	`NCT01722916` - Reducing and Removing Hyaluronic Acid Filler With Hyaluronidase	Early Phase 1
Completed	`NCT01727778` - Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma	Phase 1
Completed	`NCT01475097` - Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography	Phase 4
Terminated	`NCT01847222` - An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE™ in Healthy Volunteers.	Phase 1
Unknown status	`NCT01633099` - Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients	Phase 3
Recruiting	`NCT01297842` - Ertapenem Versus Meropenem/Imipenem for ESBL+ Gram-negative Infections	Phase 4
Completed	`NCT01284582` - Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP)	Phase 1
Completed	`NCT01556607` - A Trial to Assess the Safety, Tolerability and Pharmacokinetics of MDT-637 in Subjects With Intermittent, or Mild-to-Moderate Persistent, Asthma	Phase 1
Completed	`NCT01557270` - Efficacy and Safety Study of Dexmedetomidine as an Additive to Local Anesthetics in Shoulder Surgery	Phase 3
Completed	`NCT01319903` - Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29	Phase 1
Completed	`NCT01271569` - A Study to Assess the Efficacy and Safety of Fospropofol Disodium	Phase 1
Recruiting	`NCT04785027` - Comparison of PSORI-CM01 Formula vs Gu Ben Hua Yu Formula Combined With AD-MSCs in Psoriasis	Phase 1/Phase 2
Completed	`NCT01367873` - Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects	Phase 1
Completed	`NCT01428882` - Propofol vs. Midazolam-based Balanced Propofol for Nonanesthesiologist Moderate Sedation in Colonoscopy	Phase 4